Home sleep test vs in-lab study: which one do you need?

The 2017 AASM diagnostic guideline does not let every snoring adult pick a home test because it is easier. Polysomnography, or a technically adequate home sleep apnea test, may be used in uncomplicated people whose symptoms already point to moderate to severe obstructive apnea: excessive daytime sleepiness plus at least two of habitual loud snoring, witnessed apnea or gasping, and diagnosed hypertension. Questionnaires cannot make the diagnosis. Peripheral arterial tonometry is a sensor technology the guideline accepted as adequate. It is not an endorsement of WatchPAT or any other brand.

Is this the same as “who is excluded from a home test”?

No. A companion article on this site walks the exclusion list (heart and lung disease, neuromuscular weakness, hypoventilation, chronic opioids, stroke, severe insomnia) as the whole subject. This page is the other half of recommendation 2: who may reasonably be studied at home, what the home file can and cannot show, and how that compares with a night in the lab. If you need the “must not” column, read that piece first. If you need the “may,” stay here.

Kapur and colleagues also restated a good-practice point that gets skipped in Facebook comments: diagnostic testing is done with a comprehensive sleep evaluation and follow-up, and attended polysomnography remains the standard test when OSA is a concern. Home testing is an allowed alternative in a defined group. It is not the new gold standard.

Who may have a home sleep apnea test?

Recommendation 2 is strong: use PSG, or HSAT with a technically adequate device, to diagnose OSA in uncomplicated adults who present with signs and symptoms that indicate an increased risk of moderate to severe OSA. The at-a-glance document defines that increased risk in a sentence you can actually apply. Excessive daytime sleepiness, and at least two of these three:

• habitual loud snoring;
• witnessed apnea, gasping, or choking;
• diagnosed hypertension.

Sleepiness alone is not enough. Snoring plus a high blood-pressure reading in a pharmacy kiosk is not enough. Two of three without sleepiness is not the definition they published. People who “know they have apnea” because a spouse is tired of the noise still need the sleepiness-and-two-of-three pattern, or they need a different test for a different pretest probability.

Uncomplicated is the other gate. Absence of the cardiorespiratory, neuromuscular, hypoventilation, opioid, stroke, and severe-insomnia problems named in recommendation 4; absence of a separate sleep disorder that needs the lab (narcolepsy, a parasomnia, a movement disorder); and a home environment that can actually produce a readable night. That last item is practical. If there is no habitual sleep period, or no one can help with sensors, the home pathway fails before the file is scored.

Can a questionnaire diagnose sleep apnea?

Recommendation 1 is strong and blunt: do not use clinical tools, questionnaires, or prediction algorithms to diagnose OSA in adults in the absence of PSG or HSAT. STOP-BANG, the Berlin Questionnaire, the Epworth Sleepiness Scale, and every online “risk score” are triage. They are not a diagnosis. The 2017 task force judged that the harm of treating or labeling people from a form outweighed the convenience.

That matters in Westerville because screening forms travel. A primary-care note that says “STOP-BANG 5, likely OSA” is a reason to be evaluated. It is not a reason to skip objective testing, and it is not a reason to start CPAP from a catalog. If a dentist, a weight-loss clinic, or a website offers a diagnosis from a quiz, they are outside this guideline.

The Epworth score also does not substitute for the “excessive daytime sleepiness” clause in recommendation 2. Sleepiness is a clinical judgment. A low Epworth with crash-level drowsiness, or a high Epworth in an insomniac who is exhausted from being awake, both happen. The physician still has to take a history.

What does a home test actually record?

A technically adequate home device, in the 2017 remarks, has one of two sensor sets. Either nasal pressure, chest and abdominal respiratory inductance plethysmography, and oximetry; or peripheral arterial tonometry with oximetry and actigraphy. A technically adequate diagnostic attempt includes a minimum of four hours of technically adequate oximetry and flow (or the PAT equivalent), recorded over a night that covers the habitual sleep period. The test is administered by an accredited sleep center under a board-certified (or board-eligible) sleep physician. It is not a gadget you buy, wear, and self-interpret.

Those channels estimate respiratory events. They do not give you sleep stages from EEG. Event indices from home tests are often expressed over recording time rather than over sleep time, which is one reason the same night can look milder than it would in the lab. Central events, hypoventilation, and non-respiratory disorders are easy to under-see. That is why the exclusion list exists, and why a pretty home report in a complicated patient is a false comfort.

Is WatchPAT “AASM-endorsed”?

No. Peripheral arterial tonometry is a method: a finger sensor watches arterial-volume changes that track sympathetic bursts from airway obstruction, combined with oximetry and actigraphy. The 2017 guideline treated PAT plus those two signals as a technically adequate alternative to the nasal-pressure-and-RIP montage. That is a statement about a class of signals.

Itamar Medical issued a press release in March 2017 that read as if the new guideline had endorsed WatchPAT the product. The company then published a clarification, carried by the AASM, apologizing for language that “mistakenly implies that the new AASM clinical practice guideline formally endorses Itamar Medical’s WatchPAT product.” The guideline “was solely referring to the Peripheral Arterial Tonometry (PAT) technology as technically adequate based on evidence, and not to a specific product or device manufacturer.”

If a salesperson tells you the AASM endorsed their brand, they are repeating the error that already required a public apology. Ask which signals the device records, who scores the raw data (a technologist should review automated scoring), and who interprets it. Brand loyalty is not a channel.

This practice’s specific home-device inventory is not something to invent in an article. The clinical rule is the same regardless of the sticker on the recorder: adequate sensors, four hours of usable data, physician interpretation, and a lab night if the result is negative or the patient was never a candidate.

When is the in-lab study the better test even if you “qualify” for home?

You can meet the sleepiness-and-two-of-three pattern and still belong in the lab. Parasomnias, suspected narcolepsy, restless legs that need EMG, a need to titrate PAP the same night, and a first home test that failed all push toward polysomnography. So does diagnostic humility. PSG remains the standard test in the good-practice statement. Home testing is permitted in a slice of uncomplicated moderate-to-severe-looking OSA because the evidence supported that slice, not because the lab became obsolete.

Split-night titration is a lab procedure. If the question is “do you have OSA and what pressure works,” an attended night can answer both when the first hours are clearly moderate to severe and enough time remains to titrate. A home test cannot start CPAP for you at 2 a.m. People who already know they will need a titration, or who have failed auto-PAP setup, often save a step by going to the lab first. That is a clinical call, not a consumer upgrade.

Cost and prior authorization are real. Medicare and many commercial plans prefer home testing when the indication fits. Preference is not the same as “you are not allowed in the lab.” If the indication does not fit, the physician’s job is to document why PSG is necessary, not to squeeze you into a home code. Details of allowed amounts belong on the insurance and costs page, not in a comparison of physiology.

What does a negative home test mean?

Recommendation 3 is strong: if a single HSAT is negative, inconclusive, or technically inadequate, do PSG. Home testing is less sensitive than polysomnography. A negative result does not prove you do not have obstructive sleep apnea. It means that night, with that device, did not confirm it. The next test is the lab, not a second home kit as a matter of guideline sequence.

Inconclusive often means too little usable flow or oximetry, a night that did not cover habitual sleep, or a tracing the scorer cannot trust. Technically inadequate is the same idea with less poetry. Repeating the home test because a payer likes the CPT code is a coverage maneuver. The AASM’s published next step is attended PSG.

If symptoms are loud and the home file is quiet, believe the symptoms enough to finish the workup. Partners who hear apneas are not always wrong. Home tests miss REM-predominant and positional disease when the night did not include those states. The lab’s extra channels exist for that gap.

How should you decide before the visit?

You should not. The 2017 good-practice statement puts testing after a comprehensive evaluation. Bring the sleepiness history, the snoring and witness history, the blood-pressure diagnosis, the medication list, and the cardiac and neurologic history. The physician maps that onto recommendation 2 versus recommendation 4. You do not need to arrive having chosen a product.

If a vendor already mailed a home test, bring the raw report, not just the summary letter. Ask whether the device met the sensor minimum, whether a sleep physician interpreted it, and whether you were in the uncomplicated group. A consumer wearable that estimates “sleep apnea risk” from a watch is not HSAT.

To schedule that evaluation at 450 Alkyre Run Drive, Suite 230, call (614) 898-9340. The test that follows should match the person in the chair, not the default box in the storeroom.